PLIANT THERAPEUTICS
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avร6 and avร1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both ... IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avร1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
PLIANT THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics Pharmaceutical Recruiting Therapeutics
Founded:
2015-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.pliantrx.com
Total Employee:
101+
Status:
Active
Contact:
(910)509-3977
Email Addresses:
[email protected]
Total Funding:
694.95 M USD
Technology used in webpage:
Amazon HSTS IPv6 ReCAPTCHA V2 Amazon Virginia Region COVID-19 Ruby On Rails Token Envoy Akamai Hosted Comcast
Similar Organizations
4D Molecular Therapeutics
4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
Alzheon
Alzheon is a clinical-stage biotechnology company focused on brain health, memory and aging, developing a pipeline of innovative.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Annexon Biosciences
Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.
Click Therapeutics
Click Therapeutics delivers safe and effective digital treatments to patients in need.
Cytosorbents
Cytosorbents develops therapeutic devices used in purifying blood to treat life-threatening diseases.
Found
Found is dedicated to improving peopleโs overall wellbeing by making evidence-based weight loss accessible and affordable.
GRO Biosciences
GRO Biosciences is a biotechnology company that expands the amino acid alphabet to overcome the limitations of protein therapeutics.
PathAI
PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time.
Sarepta Therapeutics
Sarepta Therapeutics focuses on the discovery and development of precision genetic medicine to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Novartis Institutes for Biomedical Research
Novartis Institutes for Biomedical Research investment in Series C - Pliant Therapeutics
Agent Capital
Agent Capital investment in Series C - Pliant Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Pliant Therapeutics
Logos Capital
Logos Capital investment in Series C - Pliant Therapeutics
Eventide
Eventide investment in Series C - Pliant Therapeutics
Schroder Adveq
Schroder Adveq investment in Series C - Pliant Therapeutics
S-Cubed Capital
S-Cubed Capital investment in Series C - Pliant Therapeutics
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series C - Pliant Therapeutics
Redmile Group
Redmile Group investment in Series C - Pliant Therapeutics
Menlo Ventures
Menlo Ventures investment in Series C - Pliant Therapeutics
Key Employee Changes
Official Site Inspections
http://www.pliantrx.com Semrush global rank: 2.61 M Semrush visits lastest month: 6.86 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Pliant Therapeutics"
About - Pliant Therapeutics
We are a clinical stage biopharmaceutical company discovering and developing novel therapies for the treatment of fibrosis and related diseases. By โฆSee details»
Investors & Media - Pliant Therapeutics, Inc.
Corporate Profile. Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases.See details»
Team - Pliant Therapeutics
Pliantโs world-renowned founders have broad experience in fibrosis biology and small molecule chemistry, and highly experienced drug developers are translating this science into novel โฆSee details»
Pliant Therapeutics - Crunchbase Company Profile
Pliant Therapeutics reported a loss of US$0.78 per share for the first quarter of 2024, compared to a loss of US$0.67 per share in the first quarter of 2023.See details»
Pliant Therapeutics, Inc. (PLRX) - Yahoo Finance
See the company profile for Pliant Therapeutics, Inc. (PLRX) including business summary, industry/sector information, number of employees, business summary, corporate governance, โฆSee details»
Pliant Therapeutics Provides Corporate Update and Reports โฆ
[email protected] : Pliant Therapeutics, Inc. Condensed Statements of Operations (Unaudited) (In thousands, except number of shares and per share amounts) Three Months Ended June 30, โฆSee details»
Pliant Therapeutics - LinkedIn
Pliant Therapeutics | 12,058 followers on LinkedIn. We are transforming the lives of patients by developing best-in-class treatments for fibrotic diseases. | Pliant Therapeutics is a late-stage ...See details»
Pliant Therapeutics Provides Corporate Update and Reports Third โฆ
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026. SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE โฆSee details»
Pliant Therapeutics, Inc. (PLRX) Company Profile & Overview
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United โฆSee details»
Pliant Therapeutics - Craft
Pliant Therapeutics is a company focused on discovering, developing, and commercializing treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and โฆSee details»
Pliant Therapeutics Provides Corporate Update and Reports Fourth ...
For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook, and YouTube. Forward-Looking Statements Statements โฆSee details»
Overview - Pliant Therapeutics
PLN-74809 is an oral small-molecule dual-selective inhibitor of ฮฑ v ฮฒ 6 and ฮฑ v ฮฒ 1 integrins for the treatment of IPF and PSC.. While present at very low levels in healthy tissues, these integrins โฆSee details»
Pliant Therapeutics, Inc. (PLRX) - Yahoo Finance
Find the latest Pliant Therapeutics, Inc. (PLRX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Pliant Therapeutics, Inc. (PLRX) - Stock Analysis
Website https://pliantrx.com. Full Company Profile. Financial Performance. In 2023, Pliant Therapeutics's revenue was $1.58 million, a decrease of -83.69% compared to the previous โฆSee details»
Pliant Therapeutics Provides Corporate Update and Reports First โฆ
- PLN-74809 Phase 2a PET Imaging Trial Continues to Enroll with Preliminary Data Expected First Half of 2021 - PLN-74809 Phase 2a 12-week trials in IPF and PSC Currently on Track to โฆSee details»
Our Science - Pliant Therapeutics
Our Target. Transforming growth factor beta, or TGF-ฮฒ, is a key driver of fibrosis. A number of investigational therapies for fibrotic and other diseases systemically block TGF-ฮฒ, risking โฆSee details»
PLRX Stock Price Quote | Morningstar
3 days ago See the latest Pliant Therapeutics Inc Ordinary Shares stock price (PLRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.See details»
Pliant PowerPoint Presentation
Extracellular structure organization (GO:0043062) 1.42E-16 external encapsulating structure organization (GO:0045229) 1.42E-16 extracellular matrix organization (GO:0030198) 5.11E-16 โฆSee details»